Ascletis Announces Completion of Enrollment of 120 Patients in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

By /

Ascletis Pharma Inc. announces the completion of enrollment of 120 patients in the Phase III registration clinical trial of ASC40 combined with bevacizumab for treatment of recurrent glioblastoma.

Scroll to Top